Xuehai Guan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Xuehai Guan has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Bing Xu
Department of Rehabilitation, the People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, People’s Republic of China
9 shared publicationsHongmeng Lan
Department of Anaesthesiology, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China
8 shared publicationsXiaofang Huang
Department of Anaesthesiology, the First People’s Hospital of Qinzhou, Qinzhou, Guangxi, People’s Republic of China
7 shared publicationsCuiwen Zhang
Department of Anesthesiology, The First Affiliated Hospital of Guangxi Medical University
5 shared publicationsHuihe Chen
Department of Emergency, Wuming Hospital of Guangxi Medical University, Naning, Guangxi, People’s Republic of China
5 shared publicationsQiuling Chen
Department of Anaesthesiology, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China
5 shared publications
Latest Publications
- Open Access
- 1 February 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-12
Remimazolam Reduces the Cough Reflexes in Elderly Patients Undergoing Fiberoptic Bronchoscopy Under Remifentanil/Cipepofol-Based Anaesthesia: A Randomized Clinical Trial
Background: Fiberoptic bronchoscopy (FOB) is one of the most common critical procedures for diagnosis and treatment of respiratory diseases. We aimed to determine whether remimazolam reduces the cough reflexes in patients undergoing FOB under remifentanil/cipepofol-based anaesthesia. Methods: This was a single-center, single-blinded, randomized study. We included 90 adult patients underwent FOB with ASA I–III, aged 60– 90 years. Patients were randomly assigned to cipepofol (CIP) group or remimazolam-cipepofol (RMZ-CIP) group. In the CIP group, anaesthesia was induced sequentially with remifentanil and cipepofol. In the RMZ-CIP group, anaesthesia was induced sequentially with remifentanil, remimazolam, and cipepofol. A laryngeal mask airway (LMA) was inserted in both groups when the BIS ≤ 60. Anaesthesia was maintained with remifentanil and cipepofol with a BIS value between 40 and 60. The primary outcome was the incidence and severity of cough reflexes during the first FOB. The secondary outcomes included vital signs, characteristics of FOB and anaesthesia, administration of vasoactive drugs, and adverse events. Results: The incidence of cough reflexes during FOB was lower in the RMZ-CIP group than that in the CIP group (38% vs 62%, p=0.029). The total consumption of cipepofol and remifentanil was higher in CIP group than in the RMZ-CIP group (40.89 [31.41– 61.90] mg vs 27.019 [21.41– 41.91] mg, p< 0.001; 0.38 [0.42– 0.50] mg vs 0.22 [0.20– 0.26] mg, p< 0.001). Cipepofol consumption during anaesthesia induction was higher in the CIP group than in the RMZ-CIP group (p< 0.001). No difference was found in terms of vital signs, the characteristics of FOB, anaesthesia, and adverse events. Conclusion: The combination of remimazolam reduced the incidence of cough reflexes and dosage of cipepofol and remifentanil in elderly patients undergoing FOB under remifentanil/cipepofol-based anaesthesia. Clinical Trial Registration: Chinese Clinical Trial Registry (ChiCTR2300079139).
- 1 February 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-12
Open AccessRemimazolam Reduces the Cough Reflexes in Elderly Patients Undergoing Fiberoptic Bronchoscopy Under Remifentanil/Cipepofol-Based Anaesthesia: A Randomized Clinical Trial
Background: Fiberoptic bronchoscopy (FOB) is one of the most common critical procedures for diagnosis and treatment of respiratory diseases. We aimed to determine whether remimazolam reduces the cough reflexes in patients undergoing FOB under remifentanil/cipepofol-based anaesthesia. Methods: This was a single-center, single-blinded, randomized study. We included 90 adult patients underwent FOB with ASA I–III, aged 60– 90 years. Patients were randomly assigned to cipepofol (CIP) group or remimazolam-cipepofol (RMZ-CIP) group. In the CIP group, anaesthesia was induced sequentially with remifentanil and cipepofol. In the RMZ-CIP group, anaesthesia was induced sequentially with remifentanil, remimazolam, and cipepofol. A laryngeal mask airway (LMA) was inserted in both groups when the BIS ≤ 60. Anaesthesia was maintained with remifentanil and cipepofol with a BIS value between 40 and 60. The primary outcome was the incidence and severity of cough reflexes during the first FOB. The secondary outcomes included vital signs, characteristics of FOB and anaesthesia, administration of vasoactive drugs, and adverse events. Results: The incidence of cough reflexes during FOB was lower in the RMZ-CIP group than that in the CIP group (38% vs 62%, p=0.029). The total consumption of cipepofol and remifentanil was higher in CIP group than in the RMZ-CIP group (40.89 [31.41– 61.90] mg vs 27.019 [21.41– 41.91] mg, p< 0.001; 0.38 [0.42– 0.50] mg vs 0.22 [0.20– 0.26] mg, p< 0.001). Cipepofol consumption during anaesthesia induction was higher in the CIP group than in the RMZ-CIP group (p< 0.001). No difference was found in terms of vital signs, the characteristics of FOB, anaesthesia, and adverse events. Conclusion: The combination of remimazolam reduced the incidence of cough reflexes and dosage of cipepofol and remifentanil in elderly patients undergoing FOB under remifentanil/cipepofol-based anaesthesia. Clinical Trial Registration: Chinese Clinical Trial Registry (ChiCTR2300079139).
- Open Access
- 1 September 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 8879-8889
Estimation of ED50 and ED95 of Oliceridine Required to Suppress the Bronchoscopy Response in Patients Undergoing Fiberoptic Bronchoscopy Under Sedation with Cipepofol: An Up-and-Down Sequential Allocation Trial
Background: Bronchoscopy response is the main challenge during fiberoptic bronchoscopy (FOB) procedure. Opioids are commonly used to suppress bronchoscopy response. This study aimed to estimate the median effective dose (ED50) of oliceridine for suppressing bronchoscopy response during FOB under deep sedation with cipepofol. Methods: This was an up-and-down sequential allocation trial. Patients were divided into male or female groups. The initial bolus of oliceridine was 40 μg/kg. The next dose of oliceridine was determined based on prior patient’s response to FOB with 10 μg/kg step size. After seven inflection points were completed, recruitment was terminated. Following a single bolus of oliceridine, all patients received cipepofol (initial bolus:0.4 mg/kg), with infusion rates subsequently titrated between 0.2 and 1.0 mg/kg/h to maintain bispectral index (BIS) values within the 40– 60 range. A laryngeal mask (LMA) was inserted when BIS ≤ 60. The endpoints were bronchoscopy response to FOB. Dixon’s up-and-down method was used to calculate the ED50 and ED95 of oliceridine required to alleviate the bronchoscopy response. A dose-response curve was generated using probit analysis. Results: A total of 45 patients (23 males, 22 females) were enrolled in the study. The ED50 of oliceridine for suppressing the response to FOB under cipepofol sedation did not differ between males (median [interquartile range, IQR] 35.00 [35.00 to 36.00] μg/kg) and females (45.00 [35.00 to 45.00] μg/kg) (P=0.0723). Probit analysis showed the ED50 and ED95 of oliceridine required to suppress bronchoscopy response to FOB under deep sedation with cipepofol were 30.20 [95% confidence interval (CI):19.98 to 38.78] vs 40.47 [95% CI: 29.49 to 51.40] μg/kg and 46.49 [95% CI: 38.23 to 105.37] vs 57.55 [95% CI: 48.50 to 141.34] μg/kg in males and females respectively. Conclusion: The ED50 and ED95 of oliceridine required to suppress bronchoscopy response under cipepofol sedation did not differ between males and females. Trial Registration: Chictr.org.cn; identifier: ChiCTR2400086635.
- 1 September 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 8879-8889
Open AccessEstimation of ED50 and ED95 of Oliceridine Required to Suppress the Bronchoscopy Response in Patients Undergoing Fiberoptic Bronchoscopy Under Sedation with Cipepofol: An Up-and-Down Sequential Allocation Trial
Background: Bronchoscopy response is the main challenge during fiberoptic bronchoscopy (FOB) procedure. Opioids are commonly used to suppress bronchoscopy response. This study aimed to estimate the median effective dose (ED50) of oliceridine for suppressing bronchoscopy response during FOB under deep sedation with cipepofol. Methods: This was an up-and-down sequential allocation trial. Patients were divided into male or female groups. The initial bolus of oliceridine was 40 μg/kg. The next dose of oliceridine was determined based on prior patient’s response to FOB with 10 μg/kg step size. After seven inflection points were completed, recruitment was terminated. Following a single bolus of oliceridine, all patients received cipepofol (initial bolus:0.4 mg/kg), with infusion rates subsequently titrated between 0.2 and 1.0 mg/kg/h to maintain bispectral index (BIS) values within the 40– 60 range. A laryngeal mask (LMA) was inserted when BIS ≤ 60. The endpoints were bronchoscopy response to FOB. Dixon’s up-and-down method was used to calculate the ED50 and ED95 of oliceridine required to alleviate the bronchoscopy response. A dose-response curve was generated using probit analysis. Results: A total of 45 patients (23 males, 22 females) were enrolled in the study. The ED50 of oliceridine for suppressing the response to FOB under cipepofol sedation did not differ between males (median [interquartile range, IQR] 35.00 [35.00 to 36.00] μg/kg) and females (45.00 [35.00 to 45.00] μg/kg) (P=0.0723). Probit analysis showed the ED50 and ED95 of oliceridine required to suppress bronchoscopy response to FOB under deep sedation with cipepofol were 30.20 [95% confidence interval (CI):19.98 to 38.78] vs 40.47 [95% CI: 29.49 to 51.40] μg/kg and 46.49 [95% CI: 38.23 to 105.37] vs 57.55 [95% CI: 48.50 to 141.34] μg/kg in males and females respectively. Conclusion: The ED50 and ED95 of oliceridine required to suppress bronchoscopy response under cipepofol sedation did not differ between males and females. Trial Registration: Chictr.org.cn; identifier: ChiCTR2400086635.
- Open Access
- 23 July 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2534850
Remifentanil enhances the sedative effect of remimazolam during anesthesia induction in patients undergoing hysteroscopy: a randomized controlled trial
Remimazolam is a novel, short-acting benzodiazepine. This study aimed to investigate whether remifentanil enhances the sedative effect of remimazolam during anesthesia induction in patients undergoing hysteroscopy. We included 258 adult patients who underwent hysteroscopy. Patients were randomly allocated to three groups (n = 86) in a 1:1:1 ratio. Patients in the saline group received no remifentanil but normal saline during anesthesia induction. Patients in the remifentanil-1 group received low-dose remifentanil (plasma concentration 1 ng/ml), and those in the remifentanil-2 group received higher doses of remifentanil (plasma concentration 2 ng/ml) during anesthesia induction. After reaching the preset plasma concentration of remifentanil, remimazolam was administered (5 mg/kg/h) until loss of consciousness (LOC). During anesthesia maintenance, remimazolam and remifentanil were changed to ensure that the MOAA/S score reached 0. The primary outcome was the time from remimazolam administration to LOC. The secondary outcomes included the doses of remimazolam until LOC, characteristics of the operation and anesthesia, vital signs, and adverse events. The time from remimazolam administration to LOC was 154 (139, 180), 120 (104, 139), and 117 (105, 135) s in the saline group, remifentanil-1group, and remifentanil-2 groups, respectively (p < 0.05). The doses of remimazolam until LOC were 12(11, 13), 9.6(8.7, 11), and 8.9(7.9, 10) mg in the saline group, remifentanil-1group, and remifentanil-2 groups, respectively (p < 0.05). There was no significant difference in the characteristic of surgery and anesthesia between groups. Remifentanil enhances the sedative effect of remimazolam during anesthesia induction in patients undergoing hysteroscopy. The trial was registered at http://www.chictr.org.cn (ChiCTR2200062983).
- 23 July 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2534850
Open AccessRemifentanil enhances the sedative effect of remimazolam during anesthesia induction in patients undergoing hysteroscopy: a randomized controlled trial
Remimazolam is a novel, short-acting benzodiazepine. This study aimed to investigate whether remifentanil enhances the sedative effect of remimazolam during anesthesia induction in patients undergoing hysteroscopy. We included 258 adult patients who underwent hysteroscopy. Patients were randomly allocated to three groups (n = 86) in a 1:1:1 ratio. Patients in the saline group received no remifentanil but normal saline during anesthesia induction. Patients in the remifentanil-1 group received low-dose remifentanil (plasma concentration 1 ng/ml), and those in the remifentanil-2 group received higher doses of remifentanil (plasma concentration 2 ng/ml) during anesthesia induction. After reaching the preset plasma concentration of remifentanil, remimazolam was administered (5 mg/kg/h) until loss of consciousness (LOC). During anesthesia maintenance, remimazolam and remifentanil were changed to ensure that the MOAA/S score reached 0. The primary outcome was the time from remimazolam administration to LOC. The secondary outcomes included the doses of remimazolam until LOC, characteristics of the operation and anesthesia, vital signs, and adverse events. The time from remimazolam administration to LOC was 154 (139, 180), 120 (104, 139), and 117 (105, 135) s in the saline group, remifentanil-1group, and remifentanil-2 groups, respectively (p < 0.05). The doses of remimazolam until LOC were 12(11, 13), 9.6(8.7, 11), and 8.9(7.9, 10) mg in the saline group, remifentanil-1group, and remifentanil-2 groups, respectively (p < 0.05). There was no significant difference in the characteristic of surgery and anesthesia between groups. Remifentanil enhances the sedative effect of remimazolam during anesthesia induction in patients undergoing hysteroscopy. The trial was registered at http://www.chictr.org.cn (ChiCTR2200062983).
- Open Access
- 1 July 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 5653-5662
Alfentanil Enhanced the Sedation of Remimazolam During Anaesthesia Induction in Patients Undergoing Urological Day Surgery: A Randomised Controlled Trial
Background: Remimazolam is a novel benzodiazepine sedative agent. Combining opioids with sedatives exerts a synergistic effect. The aim is to investigate whether alfentanil enhances sedative effects of remimazolam during anaesthesia induction in patients undergoing urological day surgery. Methods: This was a single-centre, single-blinded, randomised clinical trial. The study was conducted between 1 September 2022 and 31 December 2023. We included 114 patients undergoing urological day surgery under general anaesthesia. Patients were randomly assigned to the RMZ-AF or AF-RMZ group (n=57). During induction, the RMZ-AF group received remimazolam then alfentanil, and the AF-RMZ group received alfentanil then remimazolam. Primary outcome was the time from remimazolam administration to loss of consciousness (LOC) during induction. Secondary outcomes included anaesthetic and surgical characteristics, vital signs, and adverse events. Results: The time from remimazolam administration to LOC was shorter in the AF-RMZ group compared with the RMZ-AF group (87.3 [25.7] s vs 132.3 [32.3] s, P< 0.0001). Similarly, the time from remimazolam administration to a bispectral index (BIS) ≤ 60 was shorter in the AF-RMZ group compared with the RMZ-AF group (168.2 [58.1] s vs 207.8 [61.6] s, P=0.0006). Although no significant difference in the total amount of remimazolam administration between groups was observed, the RMZ-AF group required a higher dose of remimazolam to achieve LOC (P< 0.0001) and to reach a BIS of ≤ 60 (P=0.0058). No significant differences were observed between groups in the total administration of alfentanil, ephedrine, rocuronium, or crystalloid infusion volumes. The most common adverse events were hypotension, hypertension, and tachycardia, with no significant difference between groups. Conclusion: Alfentanil enhanced remimazolam’s sedative effects during anaesthesia induction in patients undergoing urological day surgery. The combination of remimazolam and alfentanil for general anaesthesia would improve efficacy, reducing the adverse effects and dosage of drug. But the potential mechanisms need further study. Clinical Trial Registration: The trial was registered before patient enrolment at http://www.chictr.org.cn (ChiCTR2200064130, principal investigator: Xuehai Guan; date of registration: 27 September 2022, https://www.chictr.org.cn/showproj.html?proj=179023).
- 1 July 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 5653-5662
Open AccessAlfentanil Enhanced the Sedation of Remimazolam During Anaesthesia Induction in Patients Undergoing Urological Day Surgery: A Randomised Controlled Trial
Background: Remimazolam is a novel benzodiazepine sedative agent. Combining opioids with sedatives exerts a synergistic effect. The aim is to investigate whether alfentanil enhances sedative effects of remimazolam during anaesthesia induction in patients undergoing urological day surgery. Methods: This was a single-centre, single-blinded, randomised clinical trial. The study was conducted between 1 September 2022 and 31 December 2023. We included 114 patients undergoing urological day surgery under general anaesthesia. Patients were randomly assigned to the RMZ-AF or AF-RMZ group (n=57). During induction, the RMZ-AF group received remimazolam then alfentanil, and the AF-RMZ group received alfentanil then remimazolam. Primary outcome was the time from remimazolam administration to loss of consciousness (LOC) during induction. Secondary outcomes included anaesthetic and surgical characteristics, vital signs, and adverse events. Results: The time from remimazolam administration to LOC was shorter in the AF-RMZ group compared with the RMZ-AF group (87.3 [25.7] s vs 132.3 [32.3] s, P< 0.0001). Similarly, the time from remimazolam administration to a bispectral index (BIS) ≤ 60 was shorter in the AF-RMZ group compared with the RMZ-AF group (168.2 [58.1] s vs 207.8 [61.6] s, P=0.0006). Although no significant difference in the total amount of remimazolam administration between groups was observed, the RMZ-AF group required a higher dose of remimazolam to achieve LOC (P< 0.0001) and to reach a BIS of ≤ 60 (P=0.0058). No significant differences were observed between groups in the total administration of alfentanil, ephedrine, rocuronium, or crystalloid infusion volumes. The most common adverse events were hypotension, hypertension, and tachycardia, with no significant difference between groups. Conclusion: Alfentanil enhanced remimazolam’s sedative effects during anaesthesia induction in patients undergoing urological day surgery. The combination of remimazolam and alfentanil for general anaesthesia would improve efficacy, reducing the adverse effects and dosage of drug. But the potential mechanisms need further study. Clinical Trial Registration: The trial was registered before patient enrolment at http://www.chictr.org.cn (ChiCTR2200064130, principal investigator: Xuehai Guan; date of registration: 27 September 2022, https://www.chictr.org.cn/showproj.html?proj=179023).
- Open Access
- 2 April 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2483981
Respiratory depression in women receiving propofol/esketamine versus propofol/fentanyl for abortion surgery or curettage: a randomized clinical trial
A combination of opioids with propofol is a popular approach to non-intubated general anaesthesia; however, this method usually results in higher incidence of respiratory depression. We compared the incidence of esketamine- and fentanyl-induced respiratory depression in women undergoing abortion surgery or curettage under propofol-based non-intubated general anaesthesia. This study included 176 women (aged 18-60 years) scheduled for abortion surgery or curettage. Patients were randomized into the fentanyl or esketamine groups. Patients in the fentanyl group received fentanyl (1 µg/kg) combined with propofol intravenously. Patients in the esketamine group received subanaesthetic doses of esketamine (0.15 mg/kg) combined with propofol intravenously. The primary outcome was the incidence of respiratory depression during anaesthesia. Secondary outcomes included respiratory rate, pulse oximetry, blood pressure, heart rate, propofol dose, duration of surgery, duration of anaesthesia, and adverse events. The incidence of respiratory depression in the esketamine group was significantly lower than that in the fentanyl group (11% vs. 45%; p < .0001). Propofol administration was lower with esketamine than fentanyl. Respiratory rate, SpO2 and blood pressure were more stable in the esketamine group than in the fentanyl group. The incidences of hypotension, propofol-induced injection pain and chin lifting in the esketamine group were lower than those in the fentanyl group. The incidence of nightmares was higher in the esketamine than in the fentanyl group. The incidence of respiratory depression was lower with subanaesthetic doses of esketamine than with fentanyl in women undergoing abortion surgery or curettage under propofol-based non-intubated general anaesthesia.KEY MESSAGESOpioids combined with propofol is a popular method for non-intubated general anaesthesia; however, this method usually results in higher incidence of respiratory depression.At subanaesthetic doses, esketamine provides an analgesic effect by antagonizing the N-methyl-d-aspartate receptor.In this trial, the incidence of respiratory depression was lower with subanaesthetic doses of esketamine than with fentanyl in women undergoing abortion surgery or curettage under propofol-based non-intubated general anaesthesia.
- 2 April 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2483981
Open AccessRespiratory depression in women receiving propofol/esketamine versus propofol/fentanyl for abortion surgery or curettage: a randomized clinical trial
A combination of opioids with propofol is a popular approach to non-intubated general anaesthesia; however, this method usually results in higher incidence of respiratory depression. We compared the incidence of esketamine- and fentanyl-induced respiratory depression in women undergoing abortion surgery or curettage under propofol-based non-intubated general anaesthesia. This study included 176 women (aged 18-60 years) scheduled for abortion surgery or curettage. Patients were randomized into the fentanyl or esketamine groups. Patients in the fentanyl group received fentanyl (1 µg/kg) combined with propofol intravenously. Patients in the esketamine group received subanaesthetic doses of esketamine (0.15 mg/kg) combined with propofol intravenously. The primary outcome was the incidence of respiratory depression during anaesthesia. Secondary outcomes included respiratory rate, pulse oximetry, blood pressure, heart rate, propofol dose, duration of surgery, duration of anaesthesia, and adverse events. The incidence of respiratory depression in the esketamine group was significantly lower than that in the fentanyl group (11% vs. 45%; p < .0001). Propofol administration was lower with esketamine than fentanyl. Respiratory rate, SpO2 and blood pressure were more stable in the esketamine group than in the fentanyl group. The incidences of hypotension, propofol-induced injection pain and chin lifting in the esketamine group were lower than those in the fentanyl group. The incidence of nightmares was higher in the esketamine than in the fentanyl group. The incidence of respiratory depression was lower with subanaesthetic doses of esketamine than with fentanyl in women undergoing abortion surgery or curettage under propofol-based non-intubated general anaesthesia.KEY MESSAGESOpioids combined with propofol is a popular method for non-intubated general anaesthesia; however, this method usually results in higher incidence of respiratory depression.At subanaesthetic doses, esketamine provides an analgesic effect by antagonizing the N-methyl-d-aspartate receptor.In this trial, the incidence of respiratory depression was lower with subanaesthetic doses of esketamine than with fentanyl in women undergoing abortion surgery or curettage under propofol-based non-intubated general anaesthesia.
- Open Access
- 1 December 2024
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 18, 6487-6497
EC50 and EC95 of Remifentanil for Inhibiting Bronchoscopy Responses in Elderly Patients During Fiberoptic Bronchoscopy Under Ciprofol Sedation: An Up-and-Down Sequential Allocation Trial
Background: Opioids are used to suppress cough during fiberoptic bronchoscopy (FOB). However, evidence regarding the optimal dose of remifentanil during FOB under ciprofol sedation is limited. This study aimed to investigate the effective concentration (EC) of remifentanil required to suppress bronchoscopy responses during FOB under ciprofol sedation in elderly patients. Materials and Methods: Elderly patients aged 60 to 90 years with American Society of Anesthesiologists (ASA) physical status I–III, scheduled for FOB, were enrolled. Patients were assigned to either the male or the female group. Remifentanil was administered intravenously prior to ciprofol administration. The endpoints included responses to FOB, such as vocal cords movement, coughing, and body movement. The EC50 and EC95 values of remifentanil required to alleviate the responses to FOB were calculated using Dixon’s up-and-down method for both male and female groups. Probit analysis was used to generate a dose-response curve. Results: Thirty-nine patients (19 males and 20 females) were enrolled. The EC50 values (plasma concentration) of remifentanil for blunting FOB responses under ciprofol sedation were 3.25 (2.75 to 3.26) ng/mL and 2.25 (1.75 to 2.25) ng/mL in males and females, respectively (p = 0.0023). Probit analysis indicated that the EC50 of remifentanil required to suppress responses to FOB under ciprofol sedation was 3.102 [95% confidence interval (CI):2.694 to 3.749] ng/mL and 2.052 [95% CI: 1.345 to 2.750] ng/mL in males and females, respectively. The EC95 of remifentanil required to suppress responses to FOB under ciprofol sedation was 3.741 [95% CI: 3.366 to 7.699] ng/mL and 2.943 [95% CI: 2.456 to 9.533] ng/mL in males and females, respectively. Conclusion: The results indicate differences between males and females in the EC50 and EC95 of remifentanil needed to suppress responses to FOB under ciprofol sedation while preserving spontaneous breathing in elderly patients. Trial Registration: The study was registered with chictr.org.cn (ChiCTR2300077720; 17 th November 2023).
- 1 December 2024
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 18, 6487-6497
Open AccessEC50 and EC95 of Remifentanil for Inhibiting Bronchoscopy Responses in Elderly Patients During Fiberoptic Bronchoscopy Under Ciprofol Sedation: An Up-and-Down Sequential Allocation Trial
Background: Opioids are used to suppress cough during fiberoptic bronchoscopy (FOB). However, evidence regarding the optimal dose of remifentanil during FOB under ciprofol sedation is limited. This study aimed to investigate the effective concentration (EC) of remifentanil required to suppress bronchoscopy responses during FOB under ciprofol sedation in elderly patients. Materials and Methods: Elderly patients aged 60 to 90 years with American Society of Anesthesiologists (ASA) physical status I–III, scheduled for FOB, were enrolled. Patients were assigned to either the male or the female group. Remifentanil was administered intravenously prior to ciprofol administration. The endpoints included responses to FOB, such as vocal cords movement, coughing, and body movement. The EC50 and EC95 values of remifentanil required to alleviate the responses to FOB were calculated using Dixon’s up-and-down method for both male and female groups. Probit analysis was used to generate a dose-response curve. Results: Thirty-nine patients (19 males and 20 females) were enrolled. The EC50 values (plasma concentration) of remifentanil for blunting FOB responses under ciprofol sedation were 3.25 (2.75 to 3.26) ng/mL and 2.25 (1.75 to 2.25) ng/mL in males and females, respectively (p = 0.0023). Probit analysis indicated that the EC50 of remifentanil required to suppress responses to FOB under ciprofol sedation was 3.102 [95% confidence interval (CI):2.694 to 3.749] ng/mL and 2.052 [95% CI: 1.345 to 2.750] ng/mL in males and females, respectively. The EC95 of remifentanil required to suppress responses to FOB under ciprofol sedation was 3.741 [95% CI: 3.366 to 7.699] ng/mL and 2.943 [95% CI: 2.456 to 9.533] ng/mL in males and females, respectively. Conclusion: The results indicate differences between males and females in the EC50 and EC95 of remifentanil needed to suppress responses to FOB under ciprofol sedation while preserving spontaneous breathing in elderly patients. Trial Registration: The study was registered with chictr.org.cn (ChiCTR2300077720; 17 th November 2023).
- 2 January 2024
- Published by Wolters Kluwer Health in European Journal of Anaesthesiology
- Vol. 41 (3) , 208-216
Efficacy of remimazolam tosilate versus propofol for total intravenous anaesthesia in urological surgery
BACKGROUND: Remimazolam is a novel ultra-short-acting benzodiazepine sedative that acts on the gamma-aminobutyric acid type A receptor (GABAAR). OBJECTIVE: To compare the efficacies of remimazolam (RMZ), and propofol (PROP) combined with remifentanil and cisatracurium for total intravenous anaesthesia (TIVA) in patients undergoing urological surgery. DESIGN: A prospective, single-blind, randomised, noninferiority clinical trial. SETTING: Single centre from 1 January 2022 to 30 March 2022. PATIENTS: A total of 146 adult patients undergoing elective urological surgery. INTERVENTION: Patients were randomly allocated in a 1 : 1 ratio to the PROP or RMZ groups. In the PROP group, anaesthesia was induced with propofol at 100 mg min−1 to reach a bispectral index score (BIS) of 40 to 60. After loss of consciousness (LOC), intravenous fentanyl 3 μg kg−1 was administered, followed by cisatracurium 0.3 mg kg−1. Patients were intubated 3 min after cisatracurium administration. Anaesthesia was maintained with the combination of propofol (plasma concentration: 2.5 to 4 μg ml−1) and remifentanil (plasma concentration: 2.5 to 4 ng ml−1). In the RMZ group, anaesthesia was induced with remimazolam tosilate starting at 10 mg kg−1 h−1 to reach a BIS of 40 to 60 and maintained between 0.2 and 2 mg kg−1 h−1. After LOC, fentanyl and cisatracurium were administered and intubation was performed as in the PROP group. Anaesthesia was maintained with a combination of remimazolam (0.2 to 2 mg kg−1 h−1) and remifentanil (plasma concentration: 2.5 to 4 ng ml−1). MAIN OUTCOME MEASURES: The primary outcome was the TIVA success rate. The predefined noninferiority margin considered an absolute difference of 6% in the primary outcome between the groups. The secondary outcomes were vital signs, anaesthesia and surgery characteristics, and adverse events. RESULTS: All patients completed the trial. The success rates of TIVA with remimazolam and propofol were 100 and 98.6%, respectively. The incidence of hypotension during anaesthesia was lower in the RMZ group (26%) than in the PROP group (46.6%) (P = 0.016). The median [IQR] total consumption of ephedrine during anaesthesia was higher in the PROP group 10 [0 to 12.5] mg than in the RMZ group 0 [0 to 10] mg (P = 0.0002). The incidence of injection pain was significantly higher in the PROP group (76.7%) than in the RMZ group (0; P < 0.001). No significant differences in the controllability of the anaesthesia depth, anaesthesia and surgery characteristics, or vital signs were observed between the groups. CONCLUSION: Remimazolam demonstrated noninferior efficacy to propofol combined with remifentanil and cisatracurium for TIVA in patients undergoing urological surgery. TRIAL REGISTRATION: Chictr.org.cn, identifier: ChiCTR2100050923. CLINICAL REGISTRATION: The study was registered in the Chinese Clinical Trial Registry (ChiCTR2100050923, Principal investigator: Xuehai Guan, Date of registration: 8 November 2021, https://www.chictr.org.cn/showproj.html?proj=133466).
- 2 January 2024
- Published by Wolters Kluwer Health in European Journal of Anaesthesiology
- Vol. 41 (3) , 208-216
Efficacy of remimazolam tosilate versus propofol for total intravenous anaesthesia in urological surgery
BACKGROUND: Remimazolam is a novel ultra-short-acting benzodiazepine sedative that acts on the gamma-aminobutyric acid type A receptor (GABAAR). OBJECTIVE: To compare the efficacies of remimazolam (RMZ), and propofol (PROP) combined with remifentanil and cisatracurium for total intravenous anaesthesia (TIVA) in patients undergoing urological surgery. DESIGN: A prospective, single-blind, randomised, noninferiority clinical trial. SETTING: Single centre from 1 January 2022 to 30 March 2022. PATIENTS: A total of 146 adult patients undergoing elective urological surgery. INTERVENTION: Patients were randomly allocated in a 1 : 1 ratio to the PROP or RMZ groups. In the PROP group, anaesthesia was induced with propofol at 100 mg min−1 to reach a bispectral index score (BIS) of 40 to 60. After loss of consciousness (LOC), intravenous fentanyl 3 μg kg−1 was administered, followed by cisatracurium 0.3 mg kg−1. Patients were intubated 3 min after cisatracurium administration. Anaesthesia was maintained with the combination of propofol (plasma concentration: 2.5 to 4 μg ml−1) and remifentanil (plasma concentration: 2.5 to 4 ng ml−1). In the RMZ group, anaesthesia was induced with remimazolam tosilate starting at 10 mg kg−1 h−1 to reach a BIS of 40 to 60 and maintained between 0.2 and 2 mg kg−1 h−1. After LOC, fentanyl and cisatracurium were administered and intubation was performed as in the PROP group. Anaesthesia was maintained with a combination of remimazolam (0.2 to 2 mg kg−1 h−1) and remifentanil (plasma concentration: 2.5 to 4 ng ml−1). MAIN OUTCOME MEASURES: The primary outcome was the TIVA success rate. The predefined noninferiority margin considered an absolute difference of 6% in the primary outcome between the groups. The secondary outcomes were vital signs, anaesthesia and surgery characteristics, and adverse events. RESULTS: All patients completed the trial. The success rates of TIVA with remimazolam and propofol were 100 and 98.6%, respectively. The incidence of hypotension during anaesthesia was lower in the RMZ group (26%) than in the PROP group (46.6%) (P = 0.016). The median [IQR] total consumption of ephedrine during anaesthesia was higher in the PROP group 10 [0 to 12.5] mg than in the RMZ group 0 [0 to 10] mg (P = 0.0002). The incidence of injection pain was significantly higher in the PROP group (76.7%) than in the RMZ group (0; P < 0.001). No significant differences in the controllability of the anaesthesia depth, anaesthesia and surgery characteristics, or vital signs were observed between the groups. CONCLUSION: Remimazolam demonstrated noninferior efficacy to propofol combined with remifentanil and cisatracurium for TIVA in patients undergoing urological surgery. TRIAL REGISTRATION: Chictr.org.cn, identifier: ChiCTR2100050923. CLINICAL REGISTRATION: The study was registered in the Chinese Clinical Trial Registry (ChiCTR2100050923, Principal investigator: Xuehai Guan, Date of registration: 8 November 2021, https://www.chictr.org.cn/showproj.html?proj=133466).
- Open Access
- 20 March 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1143784
The difference in mean arterial pressure induced by remimazolam compared to etomidate in the presence of fentanyl at tracheal intubation: A randomized controlled trial
Background: Combined use of hypnotic and opioids during anesthesia inductions decreases blood pressure. Post-induction hypotension (PIHO) is the most common side effect of anesthesia induction. We aimed to compare the difference in mean arterial pressure (MAP) induced by remimazolam with that induced by etomidate in the presence of fentanyl at tracheal intubation.Methods: We assessed 138 adult patients with American Society of Anesthesiologists physical status I–II who underwent elective urological surgery. Patients were randomly allocated to receive either remimazolam or etomidate as alterative hypnotic in the presence of fentanyl during anesthesia induction. Comparable BIS values were achieved in both groups. The primary outcome was the difference in the MAP at tracheal intubation. The secondary outcomes included the characteristics of anesthesia, surgery, and adverse effects.Results: The MAP was higher in the etomidate group than in the remimazolam group at tracheal intubation (108 [22] mmHg vs. 83 [16] mmHg; mean difference, −26; 95% confidence interval [CI], −33 to −19; p < 0.0001). Heart rate was significantly higher in the etomidate group than in the remimazolam group at tracheal intubation. The patients’ condition warranted the administration of ephedrine more frequently in the remimazolam group (22%) than in the etomidate group (5%) (p = 0.0042) during anesthesia induction. The remimazolam group had a lower incidence of hypertension (0% vs. 9%, p = 0.0133), myoclonus (0% vs. 47%, p < 0.001), and tachycardia (16% vs. 35%, p = 0.0148), and a higher incidence of PIHO (42% vs. 5%, p = 0.001) than the etomidate group during anesthesia induction.Conclusion: Remimazolam was associated with lower MAP and lower heart rate compared to etomidate in the presence of fentanyl at tracheal intubation. Patients in the remimazolam group had a higher incidence of PIHO, and their condition warranted the administration of ephedrine more frequently than in the etomidate group during anesthesia induction.
- 20 March 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1143784
Open AccessThe difference in mean arterial pressure induced by remimazolam compared to etomidate in the presence of fentanyl at tracheal intubation: A randomized controlled trial
Background: Combined use of hypnotic and opioids during anesthesia inductions decreases blood pressure. Post-induction hypotension (PIHO) is the most common side effect of anesthesia induction. We aimed to compare the difference in mean arterial pressure (MAP) induced by remimazolam with that induced by etomidate in the presence of fentanyl at tracheal intubation.Methods: We assessed 138 adult patients with American Society of Anesthesiologists physical status I–II who underwent elective urological surgery. Patients were randomly allocated to receive either remimazolam or etomidate as alterative hypnotic in the presence of fentanyl during anesthesia induction. Comparable BIS values were achieved in both groups. The primary outcome was the difference in the MAP at tracheal intubation. The secondary outcomes included the characteristics of anesthesia, surgery, and adverse effects.Results: The MAP was higher in the etomidate group than in the remimazolam group at tracheal intubation (108 [22] mmHg vs. 83 [16] mmHg; mean difference, −26; 95% confidence interval [CI], −33 to −19; p < 0.0001). Heart rate was significantly higher in the etomidate group than in the remimazolam group at tracheal intubation. The patients’ condition warranted the administration of ephedrine more frequently in the remimazolam group (22%) than in the etomidate group (5%) (p = 0.0042) during anesthesia induction. The remimazolam group had a lower incidence of hypertension (0% vs. 9%, p = 0.0133), myoclonus (0% vs. 47%, p < 0.001), and tachycardia (16% vs. 35%, p = 0.0148), and a higher incidence of PIHO (42% vs. 5%, p = 0.001) than the etomidate group during anesthesia induction.Conclusion: Remimazolam was associated with lower MAP and lower heart rate compared to etomidate in the presence of fentanyl at tracheal intubation. Patients in the remimazolam group had a higher incidence of PIHO, and their condition warranted the administration of ephedrine more frequently than in the etomidate group during anesthesia induction.
- Open Access
- 15 November 2022
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 11 (11) , 803-813
Cyclin D1 mediates pain behaviour in a rat model of breast cancer-induced bone pain by a mechanism involving regulation of the proliferation of spinal microglia
Aims: The involvement of cyclin D1 in the proliferation of microglia, and the generation and maintenance of bone cancer pain (BCP), have not yet been clarified. We investigated the expression of microglia and cyclin D1, and the influences of cyclin D1 on pain threshold. Methods: Female Sprague Dawley (SD) rats were used to establish a rat model of BCP, and the messenger RNA (mRNA) and protein expression of ionized calcium binding adaptor molecule 1 (IBA1) and cyclin D1 were detected by reverse transcription-polymerase chain reaction (RT-PCR) and western blot, respectively. The proliferation of spinal microglia was detected by immunohistochemistry. The pain behaviour test was assessed by quantification of spontaneous flinches, limb use, and guarding during forced ambulation, mechanical paw withdrawal threshold, and thermal paw withdrawal latency. Results: IBA1 and cyclin D1 in the ipsilateral spinal horn increased in a time-dependent fashion. Spinal microglia proliferated in BCP rats. The microglia inhibitor minocycline attenuated the pain behaviour in BCP rats. The cyclin-dependent kinase inhibitor flavopiridol inhibited the proliferation of spinal microglia, and was associated with an improvement in pain behaviour in BCP rats. Conclusion: Our results revealed that the inhibition of spinal microglial proliferation was associated with a decrease in pain behaviour in a rat model of BCP. Cyclin D1 acts as a key regulator of the proliferation of spinal microglia in a rat model of BCP. Disruption of cyclin D1, the restriction-point control of cell cycle, inhibited the proliferation of microglia and attenuated the pain behaviours in BCP rats. Cyclin D1 and the proliferation of spinal microglia may be potential targets for the clinical treatment of BCP. Cite this article: Bone Joint Res 2022;11(11):803–813.
- 15 November 2022
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 11 (11) , 803-813
Open AccessCyclin D1 mediates pain behaviour in a rat model of breast cancer-induced bone pain by a mechanism involving regulation of the proliferation of spinal microglia
Aims: The involvement of cyclin D1 in the proliferation of microglia, and the generation and maintenance of bone cancer pain (BCP), have not yet been clarified. We investigated the expression of microglia and cyclin D1, and the influences of cyclin D1 on pain threshold. Methods: Female Sprague Dawley (SD) rats were used to establish a rat model of BCP, and the messenger RNA (mRNA) and protein expression of ionized calcium binding adaptor molecule 1 (IBA1) and cyclin D1 were detected by reverse transcription-polymerase chain reaction (RT-PCR) and western blot, respectively. The proliferation of spinal microglia was detected by immunohistochemistry. The pain behaviour test was assessed by quantification of spontaneous flinches, limb use, and guarding during forced ambulation, mechanical paw withdrawal threshold, and thermal paw withdrawal latency. Results: IBA1 and cyclin D1 in the ipsilateral spinal horn increased in a time-dependent fashion. Spinal microglia proliferated in BCP rats. The microglia inhibitor minocycline attenuated the pain behaviour in BCP rats. The cyclin-dependent kinase inhibitor flavopiridol inhibited the proliferation of spinal microglia, and was associated with an improvement in pain behaviour in BCP rats. Conclusion: Our results revealed that the inhibition of spinal microglial proliferation was associated with a decrease in pain behaviour in a rat model of BCP. Cyclin D1 acts as a key regulator of the proliferation of spinal microglia in a rat model of BCP. Disruption of cyclin D1, the restriction-point control of cell cycle, inhibited the proliferation of microglia and attenuated the pain behaviours in BCP rats. Cyclin D1 and the proliferation of spinal microglia may be potential targets for the clinical treatment of BCP. Cite this article: Bone Joint Res 2022;11(11):803–813.
- Open Access
- 20 September 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 991559
Esketamine prevents propofol-induced injection pain: Randomized controlled trial
Background: Propofol is widely used during anesthesia. However, propofol-induced injection pain (PIP) is considered an unpleasant perioperative outcome. This study aimed to investigate the efficacy of a mixture of esketamine and propofol in preventing propofol injection pain in patients undergoing general anesthesia.Methods: This was a prospective, double-blind, multicenter, and randomized controlled trial. We included 252 adult patients with the American Society of Anesthesiologists physical status I to II who underwent surgery under general anesthesia. Patients were randomly allocated in a 1:1:1:1 ratio to four groups (n = 63 per group). Group NS received a mixture of 1% propofol (20 ml) and 0.9% normal saline (1 ml), group ESK-4 received a mixture of 1% propofol (20 ml) and esketamine 4 mg (diluted with 0.9% normal saline, 1 ml), group ESK-12 received a mixture of 1% propofol (20 ml) and esketamine 12 mg (diluted with 0.9% normal saline, 1 ml), and group ESK-20 received a mixture of 1% propofol (20 ml) and esketamine 20 mg (diluted with 0.9% normal saline, 1 ml) as sedative drugs during anesthesia. The primary outcome was the incidence and distribution of different degrees of PIP. The secondary outcomes were vital signs, characteristics of surgery and anesthesia, and adverse events.Results: The incidence of PIP in group ESK-20 (33.3%) was significantly lower than that in groups NS, ESK-4, and ESK-12 (63.3%, 62.2%, and 49.1%, respectively; p < 0.01). The incidence of moderate PIP in group NS (33.3%) and group ESK-4 (22.6%) was higher than that in groups ESK-12 (7.5%) and ESK-20 (6.7%). The incidence of severe PIP in group NS (6.7%) and group ESK-4 (9.4%) was higher than that in groups ESK-12 (1.9%) and ESK-20 (0%). There were no differences in the vital signs, characteristics of surgery and anesthesia, or adverse events between the groups.Conclusion: Our results indicated that the esketamine–propofol admixture reduced the incidence of PIP in patients undergoing general anesthesia without severe side effects.
- 20 September 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 991559
Open AccessEsketamine prevents propofol-induced injection pain: Randomized controlled trial
Background: Propofol is widely used during anesthesia. However, propofol-induced injection pain (PIP) is considered an unpleasant perioperative outcome. This study aimed to investigate the efficacy of a mixture of esketamine and propofol in preventing propofol injection pain in patients undergoing general anesthesia.Methods: This was a prospective, double-blind, multicenter, and randomized controlled trial. We included 252 adult patients with the American Society of Anesthesiologists physical status I to II who underwent surgery under general anesthesia. Patients were randomly allocated in a 1:1:1:1 ratio to four groups (n = 63 per group). Group NS received a mixture of 1% propofol (20 ml) and 0.9% normal saline (1 ml), group ESK-4 received a mixture of 1% propofol (20 ml) and esketamine 4 mg (diluted with 0.9% normal saline, 1 ml), group ESK-12 received a mixture of 1% propofol (20 ml) and esketamine 12 mg (diluted with 0.9% normal saline, 1 ml), and group ESK-20 received a mixture of 1% propofol (20 ml) and esketamine 20 mg (diluted with 0.9% normal saline, 1 ml) as sedative drugs during anesthesia. The primary outcome was the incidence and distribution of different degrees of PIP. The secondary outcomes were vital signs, characteristics of surgery and anesthesia, and adverse events.Results: The incidence of PIP in group ESK-20 (33.3%) was significantly lower than that in groups NS, ESK-4, and ESK-12 (63.3%, 62.2%, and 49.1%, respectively; p < 0.01). The incidence of moderate PIP in group NS (33.3%) and group ESK-4 (22.6%) was higher than that in groups ESK-12 (7.5%) and ESK-20 (6.7%). The incidence of severe PIP in group NS (6.7%) and group ESK-4 (9.4%) was higher than that in groups ESK-12 (1.9%) and ESK-20 (0%). There were no differences in the vital signs, characteristics of surgery and anesthesia, or adverse events between the groups.Conclusion: Our results indicated that the esketamine–propofol admixture reduced the incidence of PIP in patients undergoing general anesthesia without severe side effects.